文献速递膀胱癌与上尿路尿路上皮癌

局部治疗史与晚期尿路上皮癌PD-L1抑制剂疗效的关联

Association of prior local therapy and outcomes with programmed-death ligand-1 inhibitors in advanced urothelial cancer.
PubMed 文献 · BJU Int · 2021-10-25

这项回顾性多中心队列研究纳入562例接受免疫检查点抑制剂(ICI)的晚期尿路上皮癌(aUC)患者,比较既往根治性手术(RS)或放疗(RT)与未接受者结局。二线及以上治疗中,既往RS与更高客观缓解率(ORR)、更长总生存(OS)和无进展生存(PFS)相关;一线治疗中无差异。

要点

  • 二线及以上ICI治疗中,既往RS与更高ORR、更长OS和PFS独立相关。
  • 一线ICI治疗中,既往局部治疗类型与结局无显著差异。
  • 结果需前瞻性验证,但可能影响预后评估和临床试验基准。

核心结论

  • 晚期疾病发生前接受根治性手术与二线及以上ICI治疗aUC患者更好的ORR、OS和PFS相关,一线治疗中无此关联。

研究设计与样本

  • 回顾性队列研究,收集25家机构接受ICI治疗的aUC患者临床病理、治疗和结局数据,排除初诊晚期患者,共纳入562例(一线342例,二线及以上220例)。

主要发现

  • 二线及以上治疗中,既往RS对比无RS:调整后ORR比值比2.61(95%CI 1.19-5.74),OS调整后风险比0.61(95%CI 0.42-0.88),PFS调整后风险比0.63(95%CI 0.45-0.89)。
  • 一线ICI治疗中,基于既往局部治疗类型(RS vs RT vs 无局部治疗)的结局无差异。
  • 将既往局部治疗类型(RS和RT)分别建模时,既往RS与二线及以上治疗结局的关联仍显著。

临床怎么用

  • 二线及以上ICI治疗前,既往根治性手术史可用于预后评估和临床讨论。
  • 一线ICI治疗中,既往局部治疗史不改变治疗选择或预后判断。

局限性

  • 回顾性研究,缺乏随机化,可能存在选择偏倚和混杂偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To compare clinical outcomes with programmed-death ligand-1 immune checkpoint inhibitors (ICIs) in patients with advanced urothelial carcinoma (aUC) who have vs have not undergone radical surgery (RS) or radiation therapy (RT) prior to developing metastatic disease. PATIENTS AND METHODS: We performed a retrospective cohort study collecting clinicopathological, treatment and outcomes data for patients with aUC receiving ICIs across 25 institutions. We compared outcomes (observed response rate [ORR], progression-free survival [PFS], overall survival [OS]) between patients with vs without prior RS, and by type of prior locoregional treatment (RS vs RT vs no locoregional treatment). Patients with de novo advanced disease were excluded. Analysis was stratified by treatment line (first-line and second-line or greater [second-plus line]). Logistic regression was used to compare ORR, while Kaplan-Meier analysis and Cox regression were used for PFS and OS. Multivariable models were adjusted for known prognostic factors. RESULTS: We included 562 patients (first-line: 342 and second-plus line: 220). There was no difference in outcomes based on prior locoregional treatment among those treated with first-line ICIs. In the second-plus-line setting, prior RS was associated with higher ORR (adjusted odds ratio 2.61, 95% confidence interval [CI]1.19-5.74]), longer OS (adjusted hazard ratio [aHR] 0.61, 95% CI 0.42-0.88) and PFS (aHR 0.63, 95% CI 0.45-0.89) vs no prior RS. This association remained significant when type of prior locoregional treatment (RS and RT) was modelled separately. CONCLUSION: Prior RS before developing advanced disease was associated with better outcomes in patients with aUC treated with ICIs in the second-plus-line but not in the first-line setting. While further validation is needed, our findings could have implications for prognostic estimates in clinical discussions and benchmarking for clinical trials. Limitations include the study's retrospective nature, lack of randomization, and possible selection and confounding biases.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Makrakis D, Talukder R, Diamantopoulos LN, et al. Association of prior local therapy and outcomes with programmed-death ligand-1 inhibitors in advanced urothelial cancer. BJU Int. 2021. PMID: 34597472. doi:10.1111/bju.15603

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。